Alogliptin Benzoate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Alogliptin Benzoate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
142
Registered trials
60
Result records
5
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Alogliptin Benzoate can convert its Small molecule drug profile and DPP-4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Alogliptin Benzoate (query alias: alogliptin) |
|---|---|
| Modality / target | Small molecule drug; DPP-4; DPP-4 inhibitors |
| Highest global status | Approved |
| Originator | Takeda Pharmaceutical Co., Ltd. |
| Active developers | Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Takeda Pharmaceuticals U.S.A., Inc. |
The MCP disease footprint includes Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCTs031250234 | Phase 4 | Recruiting | 50 | 1. Changes in biological age calculated using the epigenetic aging clock method based on DNA methylation patterns in peripheral blood leukocytes before and after the intervention (GrimAge version2) |
| NCT07093476 | Phase 3 | Recruiting | 171 | HbA1c |
| CTR20250730 | Not Applicable | 已完成 | 30 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus
Phase 3; n=152; evaluation: Negative. Reported fields: HbA1c = 0.1 % ( -0.63 to 0.83)
1340-P: The Association of SGLT2i vs. DPP4i on Fracture—Cohort Study of Veterans with Diabetes
Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: Fracture = 20.2 fractures per 1000 person years ( 19.1 - 21.4); Fracture = 18.1 fractures per 1000 person years ( 16.6 - 19.7)
Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: HbA1c = -0.72 % ; HbA1c = -0.7 % ; HbA1c = -0.26 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Alogliptin Benzoate addresses Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 海森生物成功收购Celltrion公司14种品牌药品，加速推进泛亚太商业布局 | Approved | Financial terms not disclosed | |
| 2021-10-08 | 华东医药引入武田制药DPP-4阿格列汀片 丰富糖尿病全产品管线布局 | Approved | Financial terms not disclosed |
| Teijin purchases Takeda's Nesina, Liovel, Inisync, Zafatek, along with their intellectual property, manufacturing, and marketing authorizations for treating type 2 diabetes in Japan. | Approved | US$1,273.3M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “A novel RP-HPLC method for the development and validation of simultaneous estimation of alogliptin and metformin hydrochloride in combined dosage forms”. The milestone feed surfaced a patent-application signal described as “Method for simultaneous estimation of alogliptin and metformin in pharmaceutical dosage form”. The milestone feed surfaced a patent-application signal described as “Preparation method of high-purity alogliptin benzoate intermediate”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
